[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Taichung Veterans General Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":629},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,47,75,99,125,151,184,209,229,254,278,300,322,347,373,401,424,449,470,494,514,539,563,585,608],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100638403","artificial-intelligence-guided-diagnosis-for-high-risk-osteoporosis-populations-a-pragmatic-randomized-clinical-trial-100638403",false,"NCT07620834","Artificial Intelligence-Guided Diagnosis for High-Risk Osteoporosis Populations: A Pragmatic Randomized Clinical Trial","Inclusion Criteria:\n\n* Aged between 40 to 80 years old\n* Identified as high-risk by the Osteoporosis Self-Assessment Tool for Taiwan Postmenopausal Women (OSTAi) \\\u003C-1 or Male Osteoporosis Self-Assessment Tool for Taiwan (MOSTAi) ≦11 based on the individual's age and weight (kg)\n* Had chest x-ray within one year\n\nExclusion Criteria:\n\n* Age \\\u003C 40 years old\n* Age \\>80 years old\n* BMI\\\u003C 18 kg\u002Fm2or \\>30 kg\u002Fm2\n* Pregnant in prior one year\n* Recorded diagnosis of osteoporosis within the past two years\n* History of prior DXA imaging (prior quantification of BMD) within 2 years\n* History of metabolic bone disease",true,"ALL","40 Years","80 Years",{"count":21,"type":22},1180,"ESTIMATED","INTERVENTIONAL",[25],"NA","Project Summary\n\nI. Project Objectives\n\nWith the rapid advancement of medical technology, smart medical devices have become one of the key components of modern healthcare. However, integrating these emerging technologies into the national health insurance (NHI) reimbursement system while ensuring their clinical value and economic benefits remains a major challenge worldwide.\n\nThe primary goal of this project is to assist commercialized smart medical device products-those that have passed TFDA review and seek NHI reimbursement-in conducting comprehensive evaluations of their clinical effectiveness and medical economic impact. Through scientific data and standardized impact assessment procedures, the project aims to provide localized evidence to support reimbursement policy decisions and facilitate the market adoption of smart medical technologies. Ultimately, this project seeks to balance therapeutic efficacy and cost control, offering a scientific foundation for NHI decision-making and paving the way for the sustainable development of AI-driven healthcare innovations.\n\nII. Implementation Methods\n\n1. Multi-center Collaborative Network\n\n   This project will be led by Taichung Veterans General Hospital (TCVGH) as the principal site, with collaboration from Kaohsiung Medical University Chung-Ho Memorial Hospital and Changhua Show Chwan Memorial Hospital. This cross-institutional, cross-regional alliance ensures diverse clinical samples, enhances the representativeness of study results, and allows evaluation of AI medical devices across different healthcare systems and environments.\n2. Clinical Trial Design and Implementation for Smart Medical Devices\n\n   The project will design and execute systematic clinical trials for smart medical devices using methodologies such as randomized controlled trials (RCTs), before-and-after studies, pragmatic RCTs (PCTs), cluster RCTs, and stepped-wedge RCTs. These rigorous designs will ensure scientific validity, reproducibility, and practical feasibility in real-world clinical settings.\n3. Health Economic Evaluation\n\n   A key component of this project is the medical economic assessment, conducted by experienced health economists through cost-effectiveness analysis. The evaluation will focus on how smart medical devices reduce healthcare costs, improve diagnostic efficiency, and enhance treatment outcomes, quantifying their economic value within the NHI system. This evidence will guide policy makers in making data-driven reimbursement decisions.\n4. Standardized Impact Assessment Process\n\n   To ensure high-quality research, the project will establish a comprehensive standardized impact assessment framework covering trial design, data collection, statistical analysis, economic evaluation, and ethical review. This standardized approach not only improves the precision of the study but also accelerates the clinical translation of AI medical devices through streamlined application and review processes.\n5. Research Case Study and Clinical Application\n\n   The featured case study in this project is \"VeriOsteo OP® Smart Bone Screening System,\" which targets early osteoporosis screening among adults aged 40 to 80 years in high-risk groups. This study will evaluate the clinical accuracy of AI-based osteoporosis screening and assess its economic contribution to healthcare cost reduction. The findings will directly inform the Ministry of Health and Welfare's NHI Administration in formulating reimbursement standards for AI medical devices.\n6. Data Sharing and Information Security\n\n   Throughout the project, all research data collection, exchange, and sharing will strictly adhere to cybersecurity and privacy regulations. The AI models involved will undergo validation to ensure the reliability and scientific rigor of the results. Furthermore, the project will promote collaboration between manufacturers and healthcare institutions to support the adoption of smart medical technologies.\n7. Final Outcomes and Future Development\n\nThe final deliverables will include a comprehensive evaluation report on the clinical and economic performance of the AI medical device, along with recommendations for NHI reimbursement application. The results will provide a reference model for future AI medical devices entering the reimbursement system and further advance the field of smart healthcare. In the long term, the center aims to expand its research to other disease domains while strengthening data security and ethical oversight to ensure the feasibility and credibility of AI applications in clinical practice.\n\nIII. Expected Outcomes and Future Vision\n\nBy implementing a multi-center collaborative framework, this project aims to promote clinical adoption and economic evaluation of smart medical devices, offering concrete data to support NHI policy-making. Over time, the project is expected to establish a robust evaluation system for AI medical devices, facilitate broader market adoption, and enhance patient outcomes whi",[28],"Osteoporosis",[30,31,32,33],"Software as a Medical Device (SaMD)","Clinical Impact Analysis","Health Economics","Standardization of NHI Reimbursement","RECRUITING","2026-05-27",{"date":37,"type":38},"2026-06-02","ACTUAL",{"date":40,"type":38},"2026-03-13",{"date":42,"type":22},"2026-11-12",{"name":44,"class":45},"Taichung Veterans General Hospital","OTHER",3,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100551158","taiwan-severe-asthma-biologic-registry-100551158","NCT06456450","Taiwan Severe Asthma Biologic Registry","TARGET","Inclusion Criteria:\n\n* Provision of informed consent prior to any study specific procedures.\n* Patient should be reviewed as well as confirmed by the National Health Insurance Administration (NHIA) or by the study board member as a Severe Asthma case.\n* Female and male aged over 18 years old.\n* Patients who are treated either with omalizumab, mepolizumab, or benralizumab after January 1, 2020.\n\nExclusion Criteria:\n\n* Lack of informed consent for participation.\n* History of Biologic usage before January 1, 2020, should be ruled out.\n* The washout period should be at least 12 months. In other words, the enrolled patients should have no experience in receiving a biological treatment or in participating relative clinical trial before his\u002Fher biologic initiation.\n* Comorbid pulmonary diseases (e.g.: Chronic Obstructive Pulmonary Disease, Bronchiectasis, Pulmonary Fibrosis, etc.) or risk factors (e.g.: smoking or environmental exposure, etc..) that could be associated with pulmonary or systemic diseases, other than Asthma.","18 Years",{"count":56,"type":22},500,"OBSERVATIONAL","This is a prospective multi-centers cohort study for registration adult patients with severe asthma and were reimbursed biologics treatment in Taiwan.\n\nThe goal of this observational study is to discover the real-world effectiveness, the impact of initiating, switching of biologics, and the possible prediction factors for selecting the best treatment option for patients.\n\nThe main question\\[s\\] it aims to answer are:\n\n1. Determine risk factors associated with poor asthma control.\n2. Support the development of effectiveness and safety of therapeutic principles\n3. To discover the real-world effectiveness of different biologics ( Clinical remission)\n4. To discover the impact of initiating biologics for severe asthma patients.\n5. To evaluate the prevalence of biologics switching and its benefits for patients.\n6. To compare the achievement rate of clinical remission among different biologics.\n\nParticipants who are treated either with omalizumab, mepolizumab, benralizumab dupilzumab or Tezepelumab after January 1, 2020 will be included in the study.",[60,61],"Pulmonary Disease","Asthma",[63,64,65],"Severe Asthma","Registry","Biologic","2026-05-17",{"date":68,"type":38},"2026-05-19",{"date":70,"type":38},"2023-11-11",{"date":72,"type":22},"2043-02-28",{"name":44,"class":45},1,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":74},"100639884","research-on-the-whole-process-of-ai-intelligent-management-system-for-the-diagnosis-and-treatment-of-inflammatory-bowel-diseases-100639884","NCT07590271","Research on the Whole Process of AI Intelligent Management System for the Diagnosis and Treatment of Inflammatory Bowel Diseases","Inclusion Criteria:\n\nInclusion criteria for the IBD group:\n\nPatients diagnosed with IBD (K50.00 to K51.919) within the specified time interval.\n\nInclusion criteria for the non-IBD group:\n\nPatients never diagnosed with IBD (K50.00 to K51.919) within the specified time interval.\n\nExclusion Criteria:\n\nPatients not within the specified time interval Deceased patients\n\nExclusion criteria for the non-IBD group:\n\nPatients not within the specified time interval Deceased patients Patients with fewer than 5 hospital visits",{"count":82,"type":22},4500,"Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic immune-mediated disorder requiring long-term management. Clinically, IBD may involve recurrent intestinal inflammation, ulcer formation, and complications such as strictures and fistulas. The etiology of IBD is associated with immune dysregulation, gut microbiome imbalance, and genetic susceptibility. Its clinical manifestations are heterogeneous; early symptoms such as abdominal pain, diarrhea, weight loss, hematochezia, or anemia often resemble gastroenteritis, irritable bowel syndrome, or infectious enterocolitis, leading to misdiagnosis and delayed diagnosis. According to international studies, the interval between initial symptom onset and confirmed diagnosis can range from several months to years, during which untreated disease progression increases the risks of hospitalization, surgery, bowel strictures, and fistulizing complications, resulting in significant impacts on patient quality of life.\n\nThis study adopts a retrospective design, analyzing our hospital's electronic medical record data from 2023 to 2025.The objective is to evaluate the performance and feasibility of an artificial intelligence (AI) model-developed and incorporating natural language processing (NLP) and phenotypic recognition algorithms-in supporting early identification and diagnosis of IBD. The model has been validated in multiple European healthcare systems and is capable of recognizing high-risk phenotypic clusters from large-scale structured and unstructured medical data. This study represents the first application of this AI technology in the Taiwanese IBD population. All data processing will occur within a de-identified and secure computing environment to ensure data privacy and information security.\n\nThe study will compare AI-generated diagnostic suggestions derived from medical records with actual clinical diagnoses to assess consistency and accuracy. The model's performance across different clinical characteristics, disease severity levels, and stages of illness will also be examined. In addition, statistical metrics such as precision and recall will be used to generate PRC curves for determining the optimal diagnostic threshold. The outcomes of this study are expected to validate the potential of AI technology in facilitating early recognition, accelerating diagnosis, and supporting clinical decision-making for IBD. The findings will provide essential data for developing localized AI models for IBD, ultimately enhancing diagnostic efficiency, shortening the diagnostic timeline, and improving long-term patient outcomes and quality of life.\n\nObjective 1：To retrospectively analyze the clinical characteristics and diagnostic pathways of patients with IBD (CD\u002FUC).\n\nObjective 2：To evaluate the performance of the AI model in identifying and providing diagnostic suggestions for high-risk IBD cases.\n\nObjective 3：To compare the accuracy and consistency between AI-generated diagnostic suggestions and actual clinical diagnoses.",[85,86,87,88,89],"Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)","Crohn's Disease (CD)","Ulcerative Colitis (UC)","Artificial Intelligence (AI)","Natural Language Processing (NLP)","NOT_YET_RECRUITING","2026-05-11",{"date":93,"type":38},"2026-05-15",{"date":95,"type":22},"2026-06-01",{"date":97,"type":22},"2027-12-31",{"name":44,"class":45},{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":74},"100357388","phase-4-tenofovir-alafenamide-versus-entecavir-for-the-treatment-of-chronic-hepatitis-b-100357388","NCT03933384","Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B","Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients more than 20 years old\n2. Chronic hepatitis B patients\n3. Patients who were indicated for hepatitis B virus antiviral therapy\n\nExclusion Criteria:\n\n1. Decompensated liver disease (Child-Pugh B \\&C)\n2. End stage renal disease (eGRF \\\u003C 15 ml\u002Fmin\u002F1.73m2)\n3. Prior use of nucleot(s)ide analogues for chronic hepatitis B\n4. Prior use of interferon for chronic hepatitis B within six months\n5. Known history of human immunodeficiency virus or hepatitis C virus co-infection\n6. Concurrent other uncontrolled malignancy\n7. Women in pregnancy or lactation\n8. Cannot conform to the study protocol of this study","20 Years",{"count":108,"type":22},140,[110],"PHASE4","To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.",[113,114],"Hepatitis B","Viral Hepatitis",[113,114,116,117],"Tenofovir alafenamide","Entecavir",{"date":119,"type":38},"2026-05-14",{"date":121,"type":38},"2019-08-19",{"date":123,"type":22},"2030-12-31",{"name":44,"class":45},{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100582063","phase-4-sglt2-inhibitor-utilization-re-perfusion-therapy-100582063","NCT06858436","SGLT2 Inhibitor Utilization Re-perfusion Therapy","The Role of SGLT2 Inhibitors in Stroke-reperfusion Injury:A Multi-Center, Randomized, Open-Label, Controlled Trial","SUPER","Inclusion Criteria:\n\n* Patients must have been diagnosed with acute ischemic stroke and large vessel occlusion by a neurologist, with confirmation supported by CT perfusion scans.\n* Patients must be scheduled to undergo mechanical thrombectomy.\n\nExclusion Criteria:\n\n* Patients with have stage 4 or 5 chronic kidney disease (estimated glomerular filtration rate (eGFR) below 30 mL\u002Fmin\u002F1.73 m² on dialysis)\n* Patients with currently taking an SGLT2i or within 3 months prior to enrollment\n* Patients with a known hypersensitivity or allergic reaction to Canagliflozin\n* Patients with type 1 diabetes mellitus\n* Patients with pregnancy or lactation",{"count":134,"type":22},150,[110],"Background:\n\nReperfusion therapies, including intravenous rt-PA and mechanical thrombectomy, significantly improve outcomes in acute ischemic stroke. However, these interventions also increase the risk of hemorrhagic transformation and malignant edema. Preclinical studies have demonstrated that Canagliflozin, an SGLT2 inhibitor, reduces astrocyte swelling and brain edema in a transient middle cerebral artery occlusion (tMCAo) model. While SGLT2 inhibitors have shown neuroprotective effects in the acute phase of ischemic stroke, their potential to mitigate hemorrhagic transformation and malignant edema following reperfusion therapy in humans remains unexamined.\n\nAims:\n\nThis study aims to evaluate the effect of SGLT2 inhibitors on hemorrhagic transformation and malignant edema in patients undergoing reperfusion therapy for acute ischemic stroke.\n\nMethods:\n\nThis is a multi-center, randomized, open-label, controlled study enrolling ischemic stroke patients aged 18 years or older who meet predefined inclusion and exclusion criteria. Participants will be randomized to receive Canagliflozin 100 mg once daily for 14 days or no additional treatment before undergoing mechanical thrombectomy. Clinical data collection will include baseline demographics, medical and medication history, NIHSS scores at admission and 24 hours post-reperfusion, stroke subtype, modified Thrombolysis in Cerebral Infarction (TICI) scores, laboratory results, and modified Rankin Scale (mRS) scores at discharge and 3 months post-stroke.\n\nThe primary outcome is to assess the association between Canagliflozin use and the severity of hemorrhagic transformation and malignant edema. Hemorrhagic transformation will be classified using the Heidelberg criteria, and malignant edema will be defined as a midline shift of ≥5 mm. Brain imaging, including CT scans at 24 hours post-intervention and additional scans as clinically indicated, will be reviewed by blinded radiologists. Brain MRA will also be performed to assess infarct size and edema progression.\n\nImportance:\n\nThis study aims to explore the potential for repurposing SGLT2 inhibitors as a therapeutic strategy in acute ischemic stroke. If Canagliflozin is shown to reduce hemorrhagic transformation and malignant edema, it could offer a novel adjunctive treatment to improve patient outcomes following reperfusion therapy.",[138],"Acute Ischemic Stroke From Large Vessel Occlusion",[140,141,142],"reperfusion therapy","SGLT2 inhibitor","malignant edema and transformation hemorrhage","2026-03-30",{"date":145,"type":38},"2026-04-03",{"date":147,"type":22},"2026-04-13",{"date":149,"type":22},"2027-10-31",{"name":44,"class":45},{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":159,"enrollmentInfo":160,"targetDuration":162,"studyType":57,"phases":4,"briefSummary":163,"conditions":164,"keywords":169,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":46},"100629782","senior-stroke-prevention-in-the-elderly-by-patent-foramen-ovale-closure-vs-anticoagulation-100629782","NCT07479147","SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation","Patent Foramen Ovale-Related Stroke Management and Outcome: Age-dependent Risk Prediction and Atrial Cardiopathy Study (SENIOR Study)","SENIOR","Inclusion Criteria:\n\n* Patient or his\u002Fher legal representative signs a written informed consent\n* Participants who have diagnosed as PFO related stroke\n* For patient aged 18-59: patient with high risk PFO feature or RoPE score ≥ 7\n* For patient aged 60-90: patient with high risk PFO feature or RoPE score ≥ 4, must include cortical infarct\n\nExclusion Criteria:\n\n* Follow-up less than 6 months\n* Extracardiac right-to-left shunt\n* Known stroke mechanism was diagnosed","90 Years",{"count":161,"type":22},400,"3 Years","Patent foramen ovale (PFO) is an important mechanism of embolic stroke of undetermined source (ESUS). Current guidelines recommend PFO closure for high-risk PFO in patients younger than 60 years, and a recent retrospective cohort study from Taichung Veterans General Hospital has shown that closure is effective and safe in older adults; however, the optimal treatment strategy for those \\>60 years and direct head-to-head comparisons of PFO closure versus direct oral anticoagulants (DOACs) remain insufficient. Robust evidence from a multicenter study combining prospective and retrospective cohorts is warranted.\n\nThe SENIOR study is a multicenter observational cohort registry with a combined retrospective and prospective design. The prospective period is from September 15, 2025 to December 31, 2031, and the retrospective period covers January 1, 2013 to September 1, 2025; target sample sizes are 400 (prospective) and 500 (retrospective). We will enroll adults with ESUS and PFO; the prospective arm will focus on patients aged \\>60 years with PFO related stroke. Treatments will be assigned as PFO closure, standard-dose DOAC, or antiplatelet agents (if DOAC intolerance) by local principal investigator. The primary outcome is recurrent ischemic stroke or transient ischemic attack. Secondary outcomes include 6-month functional outcome, all stroke, and serial comparison of atrial cardiopathy changes. Safety endpoints include peri-procedural adverse events (including newly-onset atrial fibrillation), hemorrhagic stroke, and all caused mortality. Clinical presentation, imaging, cardiac testing, biomarker, and genetic data will be collected for stratified and multivariable analyses.",[165,166,167,168],"Ischemic Stroke","Embolic Stroke of Undetermined Source","Patent Foramen Ovale (PFO)","Elderly",[170,171,172,173,174,175],"patent foramen ovale","patent foramen ovale closure","embolic stroke of undetermined source","elderly","multi-center","anticoagulation","2026-03-18",{"date":178,"type":38},"2026-03-23",{"date":180,"type":38},"2025-12-16",{"date":182,"type":22},"2031-12-31",{"name":44,"class":45},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":191,"minAge":54,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":23,"phases":194,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":74},"100622030","dextrose-hydrodissection-for-post-breast-cancer-chest-wall-and-axillary-tightness-100622030","NCT07378319","Dextrose Hydrodissection for Post-Breast Cancer Chest Wall and Axillary Tightness.","Effectiveness of Ultrasound-Guided Dextrose Prolotherapy for Persistent Chest Wall and Axillary Symptoms in Breast Cancer Survivors: A Prospective Case Series.","Inclusion Criteria:\n\n* History of breast cancer surgery (mastectomy or breast-conserving surgery), with or without axillary lymph node dissection\n* Persistent ipsilateral chest wall and\u002For axillary pain, tightness, or movement restriction lasting ≥ 3 months after surgery;\n* Clinically significant baseline symptom severity, defined as Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire ≥ 25 and\u002For pain intensity ≥ 5\u002F10 on the Numeric Rating Scale (NRS);\n* Completion of 12 weeks of standard physical therapy with no significant improvement, defined as a change in QuickDASH score from baseline to completion of therapy below the minimal clinically important difference (MCID; \\\u003C15 points ) and\u002For pain improvement \\\u003C 2 points on the NRS .\n* Age ≥ 18 years;\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Evidence of local cancer recurrence or metastatic disease;\n* Active lymphedema requiring ongoing decongestive therapy at the time of enrollment;\n* Shoulder pathology, including intra-articular or peri-articular conditions (e.g., adhesive capsulitis with marked capsular restriction, or acute rotator cuff tear,) judged by clinical assessment to be the dominant cause of symptoms.\n* Active infection, skin lesion, or unhealed surgical wound at the intended injection site;\n* Known bleeding disorders or anticoagulant use contraindicating injection;\n* Known allergy to dextrose or any components of the injection protocol;\n* Pregnancy or other medical conditions precluding participation.","FEMALE",{"count":193,"type":22},15,[25],"The goal of this clinical trial (prospective case series) is to evaluate the feasibility, safety, and preliminary clinical outcomes of ultrasound-guided dextrose prolotherapy in female breast cancer survivors with persistent ipsilateral chest wall and axillary pain and tightness who have plateaued with standard physical therapy.\n\nThe main questions it aims to answer are:\n\nDoes ultrasound-guided dextrose prolotherapy significantly improve upper extremity functional limitation (measured by the QuickDASH questionnaire)?\n\nWhat are the effects of this intervention on pain intensity (NRS), active shoulder range of motion (AROM), and anterior chest wall soft-tissue tightness (pectoralis minor muscle length)?\n\nParticipants will:\n\nUndergo a comprehensive baseline physical examination and ultrasound assessment of the symptomatic chest wall and axilla.\n\nReceive three sessions of ultrasound-guided 5% dextrose injections into targeted soft-tissue planes at 4-week intervals.\n\nContinue their designated standard rehabilitation program, including range-of-motion and stretching exercises.\n\nAttend follow-up assessments at 4-week intervals during the treatment phase, with long-term follow-up at 3 and 6 months after the final injection to evaluate the durability of the response.",[197],"Breast Cancer Females",[199,200],"breast cancer","dextrose injection","2026-03-17",{"date":203,"type":38},"2026-03-20",{"date":205,"type":38},"2025-01-11",{"date":207,"type":22},"2026-06-28",{"name":44,"class":45},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":19,"enrollmentInfo":215,"targetDuration":4,"studyType":23,"phases":217,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":228,"locationsCount":4},"100627847","early-phase-1-a-comparison-of-clinical-efficacy-of-mytocel-msk-with-amt-and-prp-injections-in-patients-with-knee-osteoarthritis-100627847","NCT07453953","A Comparison of Clinical Efficacy of Mytocel MSK With AMT and PRP Injections in Patients With Knee Osteoarthritis","Inclusion Criteria:\n\n* Male or female participants aged 18 years or older\n* Radiographic diagnosis of knee osteoarthritis with Kellgren-Lawrence (KL) grade 1 to 3\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Diagnosis of rheumatoid arthritis\n* Advanced knee osteoarthritis requiring total knee arthroplasty\n* Diagnosis of autoimmune disease\n* Severe meniscal tear or ligament injury requiring surgical intervention\n* Body mass index (BMI) greater than 30 kg\u002Fm²\n* Platelet count less than 100,000 per microliter\n* Severe genu varum or genu valgum deformity\n* Intra-articular corticosteroid injection within 3 months prior to screening\n* Intra-articular hyaluronic acid injection within 6 months prior to screening\n* Pregnant or breastfeeding women\n* Known human immunodeficiency virus (HIV) infection",{"count":216,"type":22},30,[218],"EARLY_PHASE1","Osteoarthritis is the most common joint disease, frequently affecting the knee joint. As the cartilage within the joint wears down, the balance between degeneration and regeneration is gradually disrupted, causing pain during joint movement.\n\nMytocel MSK with AMT (Autologous Micrograft Technology) is an autologous micrograft technology, the first biocompatible solution that can be directly implanted into the joint using the patient's own tissue. It possesses regenerative repair and pain-relieving effects, rapidly improving joint health and alleviating pain and stiffness. It is primarily applied to the musculoskeletal system; this therapy has been proven to have tissue regeneration potential and effectiveness in multiple medical fields. This project will harvest ear cartilage tissue, mechanically separate and precisely filter it to create a Mytocel MSK with AMT cell suspension rich in cartilage precursor cells and mesenchymal stem cell markers (CD44, CD90, CD117), which will then be injected into the knee joint cavity. It is expected to help patients repair cartilage, reduce pain, and improve their quality of life.\n\nPRP is a common treatment for knee osteoarthritis, but its effects are short-lived and require multiple injections. Mytocel MSK with AMT may achieve longer-term and more stable clinical improvement with a single application. This project will use questionnaires and MRI examinations to observe changes in pain, functional recovery, and the degree of cartilage repair before and after treatment. The data will be used to analyze and compare the differences between Mytocel MSK with AMT and PRP treatment.",[221],"Mytocel MSK With AMT","2026-03-04",{"date":224,"type":38},"2026-03-06",{"date":226,"type":22},"2026-04-01",{"date":123,"type":22},{"name":44,"class":45},{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":23,"phases":238,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":74},"100540896","esp-versus-pifb-for-analgesia-in-open-cardiac-surgery-a-randomized-control-trial-100540896","NCT06322810","ESP Versus PIFB for Analgesia in Open Cardiac Surgery: a Randomized Control Trial","Comparison of Erector Spiane Plan Block (ESPB) Versus Pecto-intercostal Fascial Block(PIFB) for Analgesia and Respiratory Function Recovery in Cardiac Surgery: a Randomized Control Trial","Inclusion Criteria:\n\n* Adults patients, elective and first-time cardiac surgery patients undergoing traditional sternotomy. Procedures include coronary artery bypass surgery, valve repair or replacement surgery, atrial and ventricular septal defect repair surgery, and other open-heart surgeries.\n\nExclusion Criteria:\n\n* 1\\. Emergency surgery 2. Anticipated combined major aortic vascular surgery 3. Already admitted to the ICU or on a ventilator before surgery.",{"count":237,"type":22},80,[25],"This clinical trial compares analgesia efficiency and recovery outcomes between two different fascial plane block techniques (ESPB vs.PIFB) in cardiac surgery patients participant population\u002Fhealth conditions\\].\n\nThe main questions it aims to answer are:\n\n* Does ESPB provide superior analgesia than PIFB\n* Do patients who receive ESPB have better recovery outcomes",[241],"Analgesia",[243,244,245],"Erector spinae plane block","Pecto-intercostal plane block","Cardiac surgery","2026-02-22",{"date":248,"type":38},"2026-02-24",{"date":250,"type":38},"2024-11-08",{"date":252,"type":22},"2026-12-31",{"name":44,"class":45},{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":277},"100558941","clinical-outcomes-of-treatment-with-immunomodulator-plus-cancer-therapies-for-patients-with-colorectal-cancer-100558941","NCT06557668","Clinical Outcomes of Treatment With Immunomodulator Plus Cancer Therapies for Patients With Colorectal Cancer","Clinical Outcomes of Treatment With Immunomodulator Plus Standard Anti-cancer Therapies for Patients With Colorectal Cancer: A Retrospective Study","Inclusion Criteria:\n\n* Aged 20 years and older.\n* Patients who have been given a diagnosis of colorectal cancer.\n* Patients had previously initiated anti-cancer therapies between January 1, 2020, and Apr 30, 2024.\n\nExclusion Criteria:\n\n* None",{"count":262,"type":22},250,"This study aims to evaluate the survival and treatment outcomes among colorectal cancer patients undergoing anti-cancer treatment, both with and without an immunomodulator.",[265],"Colorectal Cancer",[265,267,268],"Astragalus Polysaccharides","Survival","2026-01-27",{"date":271,"type":38},"2026-01-29",{"date":273,"type":38},"2024-08-20",{"date":275,"type":22},"2026-07",{"name":44,"class":45},2,{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":23,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":299,"locationsCount":4},"100620919","the-efficacy-of-ultrasonication-in-combination-with-corticosteroid-intraarticular-injection-for-arthritis-100620919","NCT07363876","The Efficacy of Ultrasonication in Combination With Corticosteroid Intraarticular Injection for Arthritis","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Diagnosed with arthritis in the limbs.\n* Inadequate response to or contraindication for oral anti-inflammatory medications.\n* Assessed by a physician as requiring intra-articular corticosteroid injection.\n\nExclusion Criteria:\n\n* History of joint replacement (prosthetic joint) in the affected area.\n* Hip joint involvement.\n* Diagnosis of gout.\n* Infectious arthritis.\n* Presence of cellulitis at the treatment site.",{"count":285,"type":22},100,[25],"This study investigates whether ultrasound therapy applied prior to intra-articular corticosteroid injection can enhance the treatment efficacy for patients with joint arthritis and assess its safety. Adult patients diagnosed with arthritis in the limbs who are indicated for corticosteroid injection are eligible, while patients with joint replacement, hip joint involvement, gout, infectious arthritis, or local cellulitis are excluded.\n\nUltrasound therapy is a valuable physical therapy tool for musculoskeletal diseases, producing therapeutic effects through thermal and non-thermal mechanisms. It can improve tissue extensibility, reduce joint stiffness, increase local blood flow, enhance metabolism during tissue repair, and facilitate drug absorption. This study evaluates whether applying ultrasound before intra-articular corticosteroid injection improves therapeutic outcomes in patients with arthritis, and assesses the safety of this combined intervention. Patients aged 18 or older, diagnosed with limb arthritis, and indicated for corticosteroid injection are eligible. Exclusion criteria include joint replacement, hip joint involvement, gout, infectious arthritis, or local cellulitis at the treatment site.",[289,290,291,292],"Arthritis","Ultrasonication","Intra-articular Injections","Rheumatology","2026-01-15",{"date":295,"type":38},"2026-01-23",{"date":297,"type":22},"2025-12-29",{"date":252,"type":22},{"name":44,"class":45},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":159,"enrollmentInfo":307,"targetDuration":4,"studyType":23,"phases":308,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":74},"100619114","phase-2-effect-of-chinese-herbal-medicine-nasal-irrigation-on-the-postoperative-care-of-chronic-rhinosinusitis-100619114","NCT07340411","Effect of Chinese Herbal Medicine Nasal Irrigation on the Postoperative Care of Chronic Rhinosinusitis","Breeze Clear","Inclusion Criteria:\n\n* 1\\. Patients with chronic rhinosinusitis who failed medical treatment 2.Patients underwent bilateral primary functional endoscopic sinus surgery.\n\nExclusion Criteria:\n\n* 1\\. Patients with a history of immunodeficiency 2.Patients with a history of sinus surgery 3.Patients who receiving antibiotic treatment within a week before functional endoscopic sinus surgery 4.Patients with a pathological diagnosis of fungal sinusitis 5.Patients with a pathological diagnosis of sinonasal tumor",{"count":237,"type":22},[309],"PHASE2","Investigators tried to evaluate the efficacy and safety of Chinese herbal medicine nasal irrigation as an adjuvant therapy after FESS.",[312,313],"Chronic Rhinosinusitis","Postoperative Care","2026-01-05",{"date":316,"type":38},"2026-01-14",{"date":318,"type":38},"2023-07-05",{"date":320,"type":22},"2026-03-31",{"name":44,"class":45},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":23,"phases":332,"briefSummary":333,"conditions":334,"keywords":337,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":346,"locationsCount":4},"100614778","the-impact-of-neuronavigation-in-rtms-for-hemiplegic-stroke-patients-100614778","NCT07284017","The Impact of Neuronavigation in rTMS for Hemiplegic Stroke Patients.","The Impact of Neuronavigation in Repetitive Transcranial Magnetic Stimulation (rTMS) for Hemiplegic Stroke Patients.","NeurorTMS-HS","Inclusion Criteria:\n\n* First-ever ischemic or hemorrhagic stroke confirmed by imaging.\n* Stroke causing unilateral upper limb weakness (MRC grade \\\u003C=3)\n* Stroke onset must be between 2 weeks and 6 months prior to enrollment (subacute phase).\n* Age between 20 and 85 years old.\n* Stable vital signs, clear consciousness, and no cognitive impairment.\n* Able to cooperate with assessments and treatment.\n* Written informed consent must be signed by the patient or a legal guardian.\n\nExclusion Criteria:\n\n* Contraindications to TMS (e.g., metallic implants in head, pacemaker, cochlear implant).\n* History of epilepsy or seizures.\n* Pregnancy.\n* Severe cognitive or communication disorders, or inability to give informed consent.\n* Unstable medical conditions affecting participation.\n* Use of certain medications, including benzodiazepines, antidepressants, muscle relaxants (baclofen, tizanidine), or ongoing botulinum toxin injections for post-stroke spasticity.\n* Modified Rankin Scale (mRS) score \\>=5 .","85 Years",{"count":216,"type":22},[25],"This is a randomized, controlled trial investigating the efficacy and precision of neuronavigation -guided repetitive transcranial magnetic stimulation (rTMS) for motor recovery in patients with subacute stroke hemiparesis.\n\nThe primary goal is to determine if using neuronavigation to precisely target the unaffected primary motor cortex (M1) improves treatment accuracy, efficiency, and clinical outcomes compared to conventional manual positioning.\n\nThe study will enroll 30 participants with first-ever stroke onset between 2 weeks and 6 months. Participants will be randomized into two parallel groups: the Experimental Group (neuronavigation-guided rTMS) and the Control Group (conventional positioning rTMS). Both groups will receive the same rTMS parameters: 1 Hz stimulation (low-frequency) over the unaffected M1, 1,200 pulses per session, administered for 10 sessions over 2 consecutive weeks.\n\nPrimary outcome measures include the change in the Fugl-Meyer Assessment (FMA) Score for the Upper Extremity and the measurement of coil positioning deviation between sessions. Assessments will be conducted at baseline (T0), post-treatment (T1, Week 3), and one month post-treatment (T2, Week 7). This study is funded in part by a research grant from the Metal Industries Research \\& Development Centre (MIRDC).",[335,336],"Stroke","Hemiparesis After Stroke",[338,339,340],"rTMS","Repetitive Transcranial Magnetic Stimulation","Neuronavigation","2025-12-14",{"date":180,"type":38},{"date":344,"type":22},"2026-01-01",{"date":252,"type":22},{"name":44,"class":45},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":23,"phases":357,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":74},"100532967","laser-acupuncture-for-chronic-migraine-100532967","NCT06219694","Laser Acupuncture for Chronic Migraine","Enhancing Chronic Migraine Preventive Therapy: Laser Acupuncture as an Add-On Treatment for Patients With Unsatisfactory Pharmacological Effect, a Pilot Randomized Controlled Trial","LAFCM","Inclusion Criteria:\n\n* patients aged above 20 years old and had CM managed pharmacologically, including preventive and\u002For acute migraine medications, and in addition, those who had refused preventive agent despite recommendation of the neurologist;\n* patients who had unsatisfactory effect of current pharmacological treatments, defined as they self-reported\n* patients who had a minimum of one-year history of migraine with or without aura.\n\nExclusion Criteria:\n\n* patients who had received another LA therapy or traditional acupuncture at baseline\n* migraine onset after the age of 50\n* cognitive or psychological impairment interfering with the participant's ability to receive LA protocol and describe symptoms\n* patients with missing data at baseline or during the follow-up period.",{"count":356,"type":22},60,[25],"A single-blind randomized controlled trial was conducted from October 2024 to May 2025. Chronic migraine patients were randomly assigned in a 1:1 ratio to receive either Laser acupuncture or sham treatment. The co-primary outcomes were changes in monthly migraine days (MMD) and acute headache medications usage days per month from baseline, and Hospital Anxiety and Depression Scale (HADS), and Beck's Depression Inventory(BDI) evaluation. Evaluations were taken at baseline and each follow-up point.\n\nAfter \\>6 months follow up as washing out time, the sham group received complementary laser acupuncture treatment and follow up for another 3 months, compared the Headache related parameters (onset, duration, pain scale, current medication for headache, menstrual cycle).",[360],"Chronic Migraine",[362,360,363,364],"Migraine","laser acupuncture","Prevention","2025-11-17",{"date":367,"type":38},"2025-11-20",{"date":369,"type":38},"2022-01-01",{"date":371,"type":22},"2025-12-01",{"name":44,"class":45},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":382,"conditions":383,"keywords":387,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":74},"100607020","3d-modeling-for-detecting-locally-advanced-rectal-cancer-with-positive-circumferential-resection-margin-100607020","NCT07183124","3D Modeling for Detecting Locally Advanced Rectal Cancer With Positive Circumferential Resection Margin","Using 3D Modeling to Detect Locally Advanced Rectal Cancer With Positive Circumferential Resection Margin","Inclusion Criteria:\n\n* Diagnosed with rectal cancer, clinical stage II-III, with no distant metastasis (M0)\n* Age over 18 years, with adequate physical status classified as American Society of Anesthesiologists (ASA) I-III, capable of receiving treatment and surgery\n* No history of other malignancies or major diseases affecting study assessment within the past three years.\n* Complete medical records, including available CT and MRI imaging.\n\nExclusion Criteria:\n\n* Patients with clinical stage I or IV rectal cancer.\n* Age under 18 years, or physical status not meeting American Society of Anesthesiologists (ASA) I-III criteria, unable to undergo surgery or related treatment.\n* Presence of other major diseases or malignancies affecting tumor assessment (e.g., diagnosis of another malignancy within the past three years, uncontrolled cardiovascular disease).\n* Incomplete medical records or imaging data, including missing required CT or MRI images.",{"count":381,"type":22},1500,"This retrospective study aims to develop an AI-assisted 3D modeling system to improve staging accuracy for stage II-III locally advanced rectal cancer (LARC). High-quality CT images from Taichung Veterans General Hospital will be used to reconstruct tumor boundaries and spatial relationships. The AI model will be trained and validated against MRI and pathology results to predict circumferential resection margin (CRM) status. Outcomes include sensitivity, specificity, accuracy, and agreement with standard imaging. This system seeks to support precise tumor staging and inform future clinical decision-making.",[384,385,386],"General Surgery","Oncology","Medical Informatics",[388,389,390,391,392],"rectal cancer","3D Modeling","deep learning","Pelvic CT Imaging","Clinical Prediction Model","2025-09-18",{"date":395,"type":38},"2025-09-19",{"date":397,"type":22},"2025-10-01",{"date":399,"type":22},"2026-07-31",{"name":44,"class":45},{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":408,"conditions":409,"keywords":412,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":74},"100472337","comparison-of-post-operation-cardiopulmonary-capacity-of-patients-underwent-conventional-and-robot-assisted-coronary-artery-bypass-graft-and-valve-replacement-surgery-100472337","NCT05430568","Comparison of Post-operation Cardiopulmonary Capacity of Patients Underwent Conventional and Robot-assisted Coronary Artery Bypass Graft and Valve Replacement Surgery","Inclusion Criteria:\n\n* patient who undergo surgery for coronary artery bypass graft or valvular replacement.\n\nExclusion Criteria:\n\n* pregnant\n* patients who receive more than one type of surgery\n* severe complications after surgery (ex. respiratory failure, stroke) and stayed in hospital for more than 2 weeks.\n* cannot perform the cardiopulmonary exercise testing\n* other contraindications for cardiopulmonary exercise testing",{"count":237,"type":22},"Robotic surgery is one of the most popular minimally invasive procedures for patients with coronary artery disease or valvular diseases. Studies have shown that, as compared to conventional sternotomy, patients underwent robot-assisted bypass grafting or valvuloplasty had less post-operation pain, blood transfusion volume during operation, re-operation rate, post-operation stroke rate and length of hospitalization. However, most studies focused on the comparison of complications of different procedures, and the investigation of cardiopulmonary function recovery is still lacking. Thus our study is to compare the functional outcomes between patients that undergo different surgical procedures.",[410,411],"Coronary Bypass Graft Stenosis","Valvular Heart Disease",[413,414,415],"cardiorespiratory fitness","robotic assisted surgery","cardiopulmonary exercise testing","2025-09-02",{"date":418,"type":38},"2025-09-09",{"date":420,"type":22},"2025-11-01",{"date":422,"type":22},"2028-05-31",{"name":44,"class":45},{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":431,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":434,"briefSummary":435,"conditions":436,"keywords":440,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":277},"100604459","phase-4-a-multi-center-rct-clinical-trial-on-personalized-precision-medicine-for-patients-with-psoriasis-and-psoriatic-arthritis-and-investigation-on-cardiovascular-biomarkers-100604459","NCT07149792","A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers","SMILE","Inclusion Criteria:\n\n* Healthy subjects\n* Psoriasis patients\n* Psoriatic arthritis patients\n* Agree to provide a blood sample\n\nExclusion Criteria:\n\n* A current history of cancer,\n* Recent hospitalization for infection or current antibiotic treatment\n* HIV infection.","75 Years",{"count":433,"type":22},50,[110],"The inclusion criteria for this study were patients aged 18 to 75 years with a confirmed diagnosis of psoriasis by a dermatologist or psoriatic arthritis by a rheumatologist. Patients with active infections or suspected malignancies were excluded.\n\nA total of 40 patients with psoriasis, with or without psoriatic arthritis, were enrolled from multiple centers in Taiwan. All participants were recruited from the outpatient clinics of either the Department of Allergy, Immunology, and Rheumatology or the Department of Dermatology in tertiary hospitals across Taiwan.\n\nParticipants were randomly assigned to one of two groups:\n\nPrescreen Strategy-Based Biologics Selection Group\n\nStandard-Based Biologics Selection Group\n\nPatients will be followed up at weeks 4, 8, 12, 24, 32, 40, 48, 56, 64, and 72. Follow-up may be extended up to 3 years if necessary.\n\nClinical assessments will include:\n\nPrimary endpoints: PASI (Psoriasis Area and Severity Index), painful joint count, swollen joint count, and DAPSA (Disease Activity in Psoriatic Arthritis) score.\n\nSecondary endpoints: DLQI (Dermatology Life Quality Index), BSA (Body Surface Area), pruritus score, and internal carotid artery thickness measured at 6 months, 1 year, and 2 years.",[437,438,439],"Psoriasis","Psoriasis Arthritis","Biologics",[441],"Prescreen, Biologics, Psoriasis, Strategic selection, Psoriatic arthritis","2025-08-24",{"date":416,"type":38},{"date":445,"type":38},"2025-07-29",{"date":447,"type":22},"2028-06-01",{"name":44,"class":45},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":23,"phases":458,"briefSummary":459,"conditions":460,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":74},"100588023","phase-2-aspirin-for-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-100588023","NCT06935994","Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease","Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Diagnosed with MASLD, which is defined by the Delphi consensus, with at least one out of five cardiometabolic criteria\n\nExclusion Criteria:\n\n1. Increased alcohol intake (average ≥ 20 g\u002Fday for women and ≥ 30 g\u002Fday for men)\n2. Glycated hemoglobin (HbA1c) level ≥ 9.0%\n3. Other causes of chronic liver disease, such as HBV, HCV, autoimmune hepatitis, Wilson's disease, etc.\n4. Liver decompensation (Child-Pugh class B or C)\n5. Liver cirrhosis with significant portal hypertension (platelet count \\\u003C 100,000\u002Fmm3, splenomegaly, and\u002For the presence of esophageal\u002Fgastric varices)\n6. High-risk EGV, defined as F2, F3, or with red-color signs, diagnosed by endoscopy within 6 months before screening\n7. Active peptic ulcer disease diagnosed by endoscopy within 6 months be- fore screening\n8. FIB-4 index \\\u003C 1.3 at screening\n9. Indicated for any anti-platelet therapy, such as history of cardiovascular events\n10. History of aspirin allergy\n11. History of bleeding disorders, such as hemophilia\n12. Pregnancy or breast feeding\n13. Severe renal impairment, which is defined as eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²\n14. Any malignancies",{"count":457,"type":22},120,[309],"Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide and a significant public health issue. MASLD may progress to liver cirrhosis and\u002For hepatocellular carcinoma. Although previous evidence suggests that aspirin has antisteatotic and antifibrotic effects on the liver, a randomized controlled trial assessing long-term efficacy and safety of aspirin in MASLD patients has yet to be conducted. This study aims to conduct a randomized controlled trial to evaluate the efficacy of aspirin in treating MASLD.",[461],"Metabolic Dysfunction Associated Steatotic Liver Disease","2025-05-06",{"date":464,"type":38},"2025-05-11",{"date":466,"type":38},"2025-05-05",{"date":468,"type":22},"2032-12-31",{"name":44,"class":45},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":479,"conditions":480,"keywords":482,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":74},"100588926","application-of-18f-fdg-petmri-for-initial-staging-in-locally-advanced-nasopharyngeal-carcinoma-100588926","NCT06947759","Application of 18F-FDG PET\u002FMRI for Initial Staging in Locally Advanced Nasopharyngeal Carcinoma","Application of 18F-FDG PET\u002FMRI as an Initial Staging Procedure for Locally Advanced Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Pathologically diagnosed with nasopharyngeal carcinoma (NPC) through endoscopic biopsy at the hospital's otolaryngology department.\n* Clinically staged as cT3-4\u002FN2-N3.\n* Age: 18 years and older.\n* Participants must voluntarily sign an informed consent form, acknowledging understanding of the study objectives and potential risks.\n\nExclusion Criteria:\n\n* Patients with poorly controlled diabetes. -Patients with a history of head and neck malignancies or a history of non- head and neck cancers with no evidence of disease for at least 3 years.\n* Patients with clinical staging of cT1-2N0-1.\n* Patients with factors that may affect PET\u002FMRI image quality, such as implanted metal devices or MRI contraindications, or those with a history of contrast agent allergies.",{"count":478,"type":22},20,"This single-center prospective observational study aims to evaluate the feasibility, cost-effectiveness, and clinical value of positron emission tomography\u002Fmagnetic resonance imaging (PET\u002FMRI) for initial staging in patients with locally advanced nasopharyngeal carcinoma (NPC). It will compare the diagnostic performance of PET\u002FMRI, including sensitivity, specificity, and staging accuracy, with traditional staging methods such as positron emission tomography\u002Fcomputed tomography (PET\u002FCT).\n\nNasopharyngeal carcinoma is prevalent in Southeast Asia and North Africa, with approximately 5% of newly diagnosed cases presenting with distant metastases. For patients with N2-3 disease and elevated Epstein-Barr virus (EBV) DNA levels, the risk of distant metastasis can reach 27.5%. Accurate detection of distant metastases at diagnosis is crucial for staging and treatment planning. Current National Comprehensive Cancer Network (NCCN) guidelines recommend fluorodeoxyglucose (18F-FDG) PET\u002FCT for staging in locally advanced nasopharyngeal carcinoma, as traditional tools (e.g., chest CT, abdominal ultrasound, bone scans) may yield false-negative results.\n\nPET\u002FMRI, as a novel imaging technique, offers potential advantages such as improved diagnostic accuracy, shorter scan times, and reduced false-positive rates. However, its clinical application is limited by high costs and equipment availability. This study will explore the clinical value and economic feasibility of PET\u002FMRI in nasopharyngeal carcinoma staging, aiming to establish its potential role in improving diagnostic pathways.",[481,385],"Nuclear Medicine",[483,484,485],"PET\u002FMRI","Nasopharyngeal carcinoma","EBV DNA","2025-04-23",{"date":488,"type":38},"2025-04-27",{"date":490,"type":22},"2025-04-30",{"date":492,"type":22},"2026-04-30",{"name":44,"class":45},{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":23,"phases":502,"briefSummary":503,"conditions":504,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":74},"100560996","migraines-accepted-laser-acupuncture-compared-in-blood-test-of-mmp2-and-cgrp-100560996","NCT06584409","Migraines Accepted Laser Acupuncture Compared in Blood Test of MMP2 and CGRP","The Comparsion of Primary Headache in Blood Test of MMP2 and CGRP: A Single Blind Randomized Sham-laser-acupuncture Controlled Study.","Inclusion Criteria:\n\n* Migraine patient under the diagnosis and classification of headache was evaluated using the ICHD-3 criteria.\n\nExclusion Criteria:\n\n* Age under 18 years old\n* Pregnancy",{"count":356,"type":22},[25],"Aims:\n\nTo investigate the efficacy of laser-acupuncture for the severity of primary headache and comorbidities, and the Lab data examination.\n\nMethods:\n\nIn this hospital-based prospective single blind randomized sham-controlled study, patients over 18 years old with primary headache will be randomly divided into two treatment arms including laser-acupuncture and sham-controlled group. The expected laser-acupuncture protocol will be bilateral BL2, GB20, EX-HN5, GB8, LI4, LR3 and midline EX-HN3 in totally eight sessions at the first month. In the sham-laser-acupuncture group, patients will receive eight sessions of laser-acupuncture for free after unblinding. We expected to track patients for at least half year. The diagnosis and classification of headache was evaluated using the ICHD-3 criteria. The severity of headache was evaluated using Migraine Disability Assessment (MIDAS) and headache diary provided by Taiwan Headache Society. The co-primary efficacy end points are change in migraine days per month and variation of MIDAS. The secondary end point is the reducing of the severity of comorbidities including headache related anxiety and depression, and both of the quality of life and sleep.\n\nIn addition, patients' characteristics will be investigated as follows:\n\n1. Sociodemographic factors (ethnicity, age, sex, body weight, BMI, blood pressure)\n2. Headache related parameters (onset, duration, pain scale, current medication for headache, menstrual cycle)\n3. Anxiety, evaluate by Hospital Anxiety and Depression Scale (HADS)\n4. Depression, evaluate by Beck's Depression Inventory\n5. Quality of life, evaluate by 36-Item Short Form Survey (SF-36)\n6. Quality of sleep, evaluate by Pittsburgh Sleep Quality Index (PSQI)\n7. Aura of headache\n8. Episodic or chronic headache (If patient diagnosed as migraine.)\n9. Nausea, vomiting, photophobia, phonophobia (If patient diagnosed as migraine.) During the following time, we will need the patient's blood samples four times, each times 20cc, all need 80cc for Lab test of MMP2, CGRP, substance P, beta-endorphin.\n\nImportance:\n\nIn our hospital, we perform laser-acupuncture for patients with headache for several years. A prospective randomized controlled study is the key tools to establish the efficacy of laser-acupuncture for primary headache, and the Lab data with MMP2, CGRP, substance P, beta-endorphin for approval. Look forward to help improve therapeutic strategies in clinical practice.",[505],"Headache, Migraine","2025-04-06",{"date":508,"type":38},"2025-04-08",{"date":510,"type":38},"2025-04-07",{"date":512,"type":22},"2027-12-01",{"name":44,"class":45},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":431,"enrollmentInfo":520,"targetDuration":4,"studyType":23,"phases":522,"briefSummary":523,"conditions":524,"keywords":526,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":538},"100578870","phase-2-perioperative-nalirifox-liposomal-irinotecan-in-combination-with-fluorouracil-leucovorin-and-oxaliplatin-in-resectable-pancreatic-adenocarcinoma-randomized-phase-ii-trial-100578870","NCT06816914","Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial","Inclusion Criteria:\n\n* previously untreated, histologically or cytologically proven PDAC\n* age between 20 and 75 years at registration\n* ECOG performance status of 0 or 1\n* AJCC (8th edition) clinical stage I or II with measurable disease (CT or MRI) in the pancreas. (positron emission tomography scan alone not allowed)\n* Surgically resectable disease according to NCCN criteria (Version 1.2023 - May 4, 2023):\n* no arterial tumor contact (celiac axis, superior mesentery artery, or common hepatic artery).\n* no tumor contact with the superior mesentery vein or portal vein or ≤180° contact without vein contour irregularity.\n* adequate major organ functions\n* Women of childbearing potential (including women with chemical menopause or no menstruation for other medical reasons) must agree to use contraception from the time ofinformed consent until 6 months or more after the last dose of investigational products. Also, women must agree not to breastfeed from the time of informed consent until 6 months or more after the last dose of the investigational product.\n* Men must agree to use contraception from the start of study treatment until 3 months or more after the last dose of the investigational product.\n* Participants must have signed written informed consent form in accordance with regulatory and institutional guidelines.\n\nExclusion Criteria:\n\n* presence of clinically significant co-morbid medical conditions within 4 weeks prior registration judged by Investigators\n* severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) in past 6 months\n* New York Heart Association class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure or known abnormal electrocardiogram (ECG) with clinically significant abnormal findings in past 6 months\n* interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity within 28 days prior to registration\n* presence of diarrhea ≥ CTCAE v.5.0 grade 2\n* concomitant systemic infection requiring treatment\n* prior organ allograft or allogeneic bone marrow transplantation\n* known history of testing positive for human immunodeficiency virus or known acquired immunodeficiency syndrome\n* prior or concurrent malignancies within the last 3 years, with the exception of carcinoma in situ of the cervix, or basal type skin cancer\n* any major surgery within 4 weeks of study treatment. Participants must have recovered from the effects of major surgery or significant traumatic injury at least 4 weeks before study treatment.\n* pregnant women or nursing mothers, or positive pregnancy tests\n* severe mental disorder\n* current use or any use in past 2 weeks of strong cytochrome P450 3A4 enzyme inducers\u002Finhibitors and\u002For strong UGT1A inhibitors\n* known hypersensitivity to any of the components of study drugs",{"count":521,"type":22},84,[309],"To explore the safety and activity of NALIRIFOX (liposomal irinotecan in combination with fluorouracil, leucovorin, and oxaliplatin) in the perioperative and adjuvant treatment in resectable pancreatic adeneocarcinoma.",[525],"Resectable Pancreatic Adenocarcinoma",[527,528,529],"Perioperative","NALIRIFOX","resectable pancreatic adenocarcinoma","2025-02-18",{"date":532,"type":38},"2025-02-20",{"date":534,"type":22},"2025-03-05",{"date":536,"type":22},"2028-02-05",{"name":44,"class":45},9,{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":23,"phases":548,"briefSummary":549,"conditions":550,"keywords":552,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":561,"locationsCount":562},"100579049","self-management-of-blood-pressure-in-resistant-hypertension-100579049","NCT06819241","Self-Management of Blood Pressure in Resistant Hypertension","Effectiveness of Self-Management of Blood Pressure on the Management of Resistant Hypertension","Inclusion Criteria:\n\n1. ≥18 years of age\n2. receiving ≥3 antihypertensive medications of different classes, including a diuretic, and baseline BP \\>130\u002F80 mmHg; or receiving ≥ 4 medications regardless of BP\n\nExclusion Criteria:\n\n1. unable to conduct self-monitor BP because of cognitive dysfunction\n2. poor adherence to medication\n3. poor digital capabilities\n4. pregnant\n5. terminal disease\n6. an acute cardiovascular event in the previous 3 months",{"count":547,"type":22},600,[25],"The trial is a 12-month randomized, parallel-group study comparing three arms: (1) HBP self-management with AI chatbot support, (2) HBP self-management without AI chatbot support, and (3) usual care. The primary objective is to evaluate differences in blood pressure changes and medication compliance between groups at 6 and 12 months.",[551],"Resistant Hypertension",[553,554],"resistant hypertension","self-management of blood pressure","2025-02-10",{"date":557,"type":38},"2025-02-11",{"date":559,"type":22},"2025-02-16",{"date":149,"type":22},{"name":44,"class":45},5,{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":570,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":74},"100484051","tenofovir-alafenamide-switch-therapy-in-chronic-hepatitis-b-100484051","NCT05583006","Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B","A Prospective Cohort Study of Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B Patients Who Are Unsatisfied to Entecavir Therapy","Inclusion Criteria:\n\n1. At least 20 years of age\n2. Detectable serum HBsAg\n3. Chronic HBV infection under ETV therapy\n4. ETV users who are unsatisfied with the efficacy and\u002For feel inconvenient of ETV therapy\n5. No contraindications for TAF switch therapy\n6. HBV antiviral period expectancy for at least 1 year\n\nExclusion Criteria:\n\n1. End stage renal disease (estimated glomerular filtration rate \\[eGRF\\]\\\u003C 15 mL\u002Fmin\u002F1.73m2) without dialysis\n2. Co-infected with human immunodeficiency virus, hepatitis C virus, or hepatitis D virus\n3. Any active malignancies\n4. Under immunosuppressants\n5. Known allergy to tenofovir-contained regimens",{"count":356,"type":22},"Chronic hepatitis B (CHB) patients may be unsatisfied to entecavir (ETV) therapy due to the inconvenience in drug taking, i.e., fasting for more than 2 hours and\u002For dose adjustment according to estimated glomerular filtration rate (eGFR). However, tenofovir alafenamide (TAF) has been approved to be highly effective and safe in patients with CHB, and is convenient in drug taking, i.e., once daily regardless food taking and renal function.Therefore,TAF can be a good option in CHB patients who are unsatisfied to ETV therapy. The aim of this prospective cohort study is to assess the improvement on satisfaction (including drug adherence) of TAF switch therapy in CHB patients who are unsatisfied to ETV therapy. In addition, with expected adherence improvement in TAF switch therapy, the efficacy of TAF switch therapy may be improved, and the efficacy benefits can be evaluated by the changes of some novel biomarkers, such as HBV core-related antigen (HBcrAg). The investigators therefore aim to conduct a prospective cohort study of TAF switch therapy for CHB patients who are unsatisfied to ETV therapy.",[573,574,575,576],"Patient Satisfaction","Drug Adherence","Efficacy, Self","Safety Issues","2025-01-07",{"date":579,"type":38},"2025-01-09",{"date":581,"type":38},"2023-11-06",{"date":583,"type":22},"2028-12-30",{"name":44,"class":45},{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":17,"minAge":162,"maxAge":592,"enrollmentInfo":593,"targetDuration":4,"studyType":23,"phases":595,"briefSummary":596,"conditions":597,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":74},"100553689","the-effect-of-watching-video-and-blowing-paper-pinwheels-in-children-100553689","NCT06489353","The Effect of Watching Video and Blowing Paper Pinwheels in Children","The Effect of Watching Video and Blowing Paper Pinwheels on Pain and Fear in Children Undergoing Venipuncture.","Inclusion Criteria:\n\n* aged 3-6 years.\n* undergoing intravenous infusion or blood draw during the hospital stay.\n\nExclusion Criteria:\n\n* chronic diseases.\n* developmental delays or epilepsy.\n* difficulty speaking.\n* hearing or visual impairments.\n* use sedatives within the past 6 hours.\n* history of fainting during intravenous infusion or blood draw.","6 Years",{"count":594,"type":22},93,[25],"The goal of this clinical trial is to evaluate if watching videos and blowing paper pinwheels can reduce pain and fear in children undergoing venipuncture. The participant population includes hospitalized children aged 3-6 years old undergoing venipuncture for the first time.\n\nThe main questions it aims to answer are:\n\n1. Does watching videos reduce pain and fear during venipuncture in children?\n2. Does blowing paper pinwheels reduce pain and fear during venipuncture in children?\n\nResearchers will compare a group watching videos and a group blowing paper pinwheels to a control group receiving standard care to see if these interventions reduce pain and fear.\n\nParticipants will:\n\n* Watch their preferred cartoons on an iPad during the venipuncture process.\n* Blow paper pinwheels to distract themselves during the venipuncture process.\n* Be accompanied by a family member who will help in holding the child and providing comfort.",[598,599],"Pain","Fear","2024-11-18",{"date":602,"type":38},"2024-11-21",{"date":604,"type":38},"2024-07-18",{"date":606,"type":22},"2025-12-30",{"name":44,"class":45},{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":614,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":615,"conditions":616,"keywords":618,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":4},"100561591","factors-influencing-wound-healing-after-anal-fistula-surgery-100561591","NCT06592157","Factors Influencing Wound Healing After Anal Fistula Surgery","Inclusion Criteria:\n\n* Patients over 18 years old.\n* Have undergone anal fistula surgery with complete surgical records.\n* No significant surgical contraindications, such as:Acute infection or inflammation,Severe cardiopulmonary insufficiency,Coagulation disorders,Immunodeficiency,Local skin lesions.\n* Understand and are willing to participate in the study.Willing to sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients under 18 years of age.\n* Pregnant or breastfeeding women.\n* Individuals with pre-existing severe heart, liver, or kidney diseases.\n* Individuals with active infections or systemic diseases.\n* Individuals who have previously undergone similar surgeries.\n* Individuals with immune dysfunction (such as HIV infection).",{"count":547,"type":22},"The objective of this observational study is to analyze the factors influencing wound healing after anal fistula surgery and to assess the effectiveness of interventions in improving overall patient outcomes post-surgery. The primary questions this study aims to answer are:\n\n1. Does the use of the growth factor (New Epi) contribute to accelerating wound healing, reducing the risk of infection, and enhancing patient recovery speed after surgery?\n2. Do other factors, such as infection, nutritional status, diabetes, surgical methods, patient age and overall health, immune status, and lifestyle habits, affect the healing of surgical wounds?",[617],"Anal Fistula Surgery",[619,617,620],"Ep ithelial Growth Factor New Epi","Wound Care","2024-09-08",{"date":623,"type":38},"2024-09-19",{"date":625,"type":22},"2024-09-10",{"date":627,"type":22},"2026-06-30",{"name":44,"class":45},""]